argenx SE
(NASDAQ : ARGX)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc -0.35%55.656.5%$168.55m
CTLTCatalent, Inc. 1.77%78.842.1%$114.23m
VRXValeant Pharmaceuticals International, Inc. -1.81%17.1014.1%$100.62m
JAZZJazz Pharmaceuticals Plc 0.33%105.902.4%$76.89m
UTHRUnited Therapeutics Corp. 0.88%116.9814.3%$68.05m
BHCBausch Health Cos., Inc. -1.90%17.080.0%$64.22m
ICPTIntercept Pharmaceuticals, Inc. -0.05%43.1116.8%$62.94m
PCRXPacira Biosciences, Inc. -1.01%55.0210.3%$54.22m
AXSMAxsome Therapeutics, Inc. 2.41%78.591.9%$49.35m
ZGNXZogenix, Inc. 2.27%27.097.5%$48.32m
PRGOPerrigo Co. Plc 0.24%55.676.8%$43.62m
MYOKMyoKardia, Inc. 0.87%91.411.8%$43.59m
GWPHGW Pharmaceuticals Plc 3.34%136.606.2%$42.60m
ARGXargenx SE -0.32%250.010.0%$41.90m
ICLRICON plc 2.48%176.054.3%$38.25m

Company Profile

argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.